With the collaboration, Zylox Medical, the Company's peripheral vascular business unit, plans to launch the "Zylox-Hicicare Guidewire Family" products to a...
Medtronic plc (NYSE: MDT), the global leader in medical technology, today announced U.S. Food and Drug Administration (FDA) approval of its Mini...
The Phase 3 ELEVATE study demonstrated atogepant is effective and well-tolerated for the preventive treatment of episodic migraine in people who previous...
The Centers for Disease Control and Prevention today reported 26.7 percent of people with autism spectrum disorder have "profound autism". It is the first ...
"We are pleased to add CUVRIOR to the list of PANTHERx® medications. The PANTHERx team works hard to make a positive difference in the lives of ou...
The human brain has a sweet tooth, burning through nearly one quarter of the body's sugar energy, or glucose, each day. Now, researchers at Gladstone Insti...
Cali Biosciences Co., Ltd. (hereinafter referred to as "Cali" or "Cali Biosciences"), a biopharmaceutical company focused on the research and development o...
Juntendo University, Sysmex Corporation, and ThinkCyte K.K. have announced a collaborative research partnership to advance the early detection and treatmen...
"Today's approval is an important advance in cell therapy treatment in patients with blood cancers," said Peter Marks, M.D., Ph.D., director of the FDA's C...
Shionogi & Co., Ltd. (Head Office: Osaka, Japan; Chief Executive Officer: Isao Teshirogi, Ph.D.; hereafter "Shionogi") announces key data for Fetcroja&...
Otsuka Pharmaceutical Development & Commercialization, Inc., (Otsuka) and Lundbeck Pharmaceuticals LLC (Lundbeck) announce the Joint Meeting of the Psy...
A preclinical study using stem cells to produce progenitor photoreceptor cells—light-detecting cells found in the eye—and then transplant...
Zebra Technologies Corporation (NASDAQ: ZBRA), an innovator at the front line of business with solutions and partners that deliver a performanc...
The FDA has also recently granted an orphan drug designation (ODD) to GIVI-MPC. Current treatments for DMD have limited therapeutic potential as unfortunat...
© 2024 Biopharma Boardroom. All Rights Reserved.
